Page 9 - Diffusion Pharmaceuticals News Today

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN – Get Rating) was the target of a significant growth in short interest in the month of April. As of April 30th, there was short interest totalling 83,000 shares, a growth of 336.8% from the April 15th total of 19,000 shares. Approximately 4.1% of the company’s stock are short sold. Based […]

Cyclerion Therapeutics (NASDAQ:CYCN – Get Rating) and Diffusion Pharmaceuticals (NASDAQ:DFFN – Get Rating) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, earnings, dividends, analyst recommendations, institutional ownership, risk and valuation. Risk & Volatility Cyclerion Therapeutics has a beta of […]

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN – Get Rating) was the recipient of a large decrease in short interest in the month of April. As of April 15th, there was short interest totalling 19,000 shares, a decrease of 97.7% from the March 31st total of 822,700 shares. Based on an average trading volume of 49,200 shares, the […]

Brokerages expect that Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN – Get Rating) will post ($0.04) earnings per share for the current quarter, Zacks Investment Research reports. Zero analysts have made estimates for Diffusion Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.03) and the lowest estimate coming in at ($0.04). Diffusion Pharmaceuticals posted earnings of […]

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN – Get Rating) saw a large growth in short interest in March. As of March 31st, there was short interest totalling 822,700 shares, a growth of 37.0% from the March 15th total of 600,500 shares. Based on an average daily trading volume, of 1,020,000 shares, the days-to-cover ratio is presently 0.8 […]

Read the latest stock market news on MarketBeat. Get real-time analyst ratings, dividend information, earnings results, financials, headlines, insider trades and options data for any stock.

According to Global Market Insights, the market for biotech in 2020 was valued at $497 billion, and it is forecasted to grow to $952.0 billion in 2027, at a CAGR of more than 9.4% between 2021 and 2027...

StockNews.com began coverage on shares of Diffusion Pharmaceuticals (NASDAQ:DFFN – Get Rating) in a research report issued on Sunday. The brokerage set a “sell” rating on the stock. Diffusion Pharmaceuticals stock opened at $0.25 on Friday. The company has a market capitalization of $25.69 million, a PE ratio of -0.97 and a beta of 1.46. […]

Diffusion Pharmaceuticals Inc. (NASDAQ:DFFN – Get Rating) – Zacks Investment Research cut their FY2022 earnings per share estimates for Diffusion Pharmaceuticals in a report issued on Wednesday, March 23rd. Zacks Investment Research analyst D. Bautz now forecasts that the company will post earnings of ($0.17) per share for the year, down from their prior forecast […]

A 33-year-old man with intermittent asthma presented with 3 months of dyspnea on exertion, which developed approximately 2 weeks after infection with SARS-CoV-2